NASDAQ$PMVP
Pmv Pharmaceuticals Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
PMV Pharma's financial results for Q4 2021 were reported, highlighting the progress of PC14586 and the expansion of the pipeline.
PMV Pharma reported its Q4 and full year 2021 financial results, with a focus on the continued development of PC14586 and the expansion of its pipeline. The company ended the year with a strong cash position of $314.1 million.
- Continued progress with Phase 1/2 study of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation.
- Advanced WIP1 inhibitor program into lead optimization.
- Binh Vu Ph.D. promoted to Senior Vice President, Discovery Research and CMC and Melissa Dumble Ph.D. to Senior Vice President, Preclinical Development and Translational Science.
- Kirsten Flowers appointed to the Board of Directors.
Headline financials
Revenue & EPS history
PMV Pharma · Revenue · Quarterly
$0
Forward guidance
PMV Pharma anticipates a productive 2022, focusing on the development of PC14586 and advancing its discovery pipeline.
Tailwinds
- Steady progress in the development of PC14586.
- Initial data from ongoing Phase 1/2 trial expected in the first half of 2022.
- Strong leadership.
- Solid balance sheet.
- Advancement of discovery pipeline of small molecule, tumor-agnostic precision medicine products.
Headwinds
- Success of product candidate development activities and planned clinical trials are subject to risk.
- Company's ability to execute on its strategy and operate as an early clinical stage company is subject to risk.
- Potential for clinical trials of PC14586 or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results.
- Company's ability to fund operations are subject to risk.
- Impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+2.7%
Avg return
Earnings day
+3.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
67%
14 / 21 earnings
Positive
+29.5%
Q2 2023
Best reaction
-18.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.0% | +8.0% | -10.7% | |
| Q3 2025 | +8.5% | +6.8% | -7.5% | |
| Q2 2025 | -4.1% | -6.6% | -3.9% | |
| Q1 2025 | +4.2% | +7.5% | +28.9% | |
| Q4 2024 | -3.6% | -10.2% | -27.0% | |
| Q3 2024 | +4.8% | +0.6% | -4.2% | |
| Q1 2024 | -5.6% | -0.9% | -23.1% | |
| Q4 2023 | +3.9% | +3.9% | -6.1% | |
| Q3 2023 | +7.5% | +19.9% | +24.2% | |
| Q2 2023 | +29.5% | +20.0% | -10.8% | |
| Q1 2023 | +11.9% | +14.7% | +8.5% | |
| Q4 2022 | -18.1% | -19.6% | -33.8% | |
| Q3 2022 | -3.7% | +11.2% | -2.6% | |
| Q2 2022 | +0.4% | -1.3% | -17.6% | |
| Q1 2022 | +2.2% | +9.0% | -13.7% | |
| Q4 2021 | +10.3% | +1.3% | +31.4% | |
| Q3 2021 | +0.4% | +2.4% | -1.6% | |
| Q2 2021 | -1.2% | -5.2% | -10.2% | |
| Q1 2021 | +12.7% | +15.6% | +18.5% | |
| Q4 2020 | +0.7% | -0.7% | -5.9% | |
| Q3 2020 | -5.1% | -5.2% | +40.3% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro